Viking Therapeutics (VKTX) stock drops as its oral obesity drug VK2735 trails Novo's (NVO) oral Wegovy and Lilly's (LLY) ...

The oral formulation led to up to 12.2% weight loss over three months, a weaker outcome versus late-stage treatments from Eli ...

Viking Therapeutics' stock drops 40% despite strong Phase 2 weight-loss drug results. See here to know why I remain ultra ...

When bad news drops, investors have a tendency to sell first and ask questions later. Let's take a closer look at why Viking ...

We recently published 10 Stocks Hammered Harder Than Wall Street. Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of Tuesday’s ...

Shares of Viking Therapeutics VKTX plunged 42% yesterday after it reported top-line data from the phase II VENTURE-Oral ...

Viking Therapeutics said Tuesday its experimental weight-loss pill helped patients lose 12.2% of their body weight in a ...

Viking Therapeutics (VKTX) shares crashed nearly 29% in today’s trade after the company’s much-anticipated weight-loss pill ...

Viking Therapeutics (VKTX) stock dove on Tuesday following the release of data from a Phase 2 clinical trial of VK2735. This is the pharmaceutical company’s dual agonist of the glucagon-like peptide 1 ...

The clinical-stage biopharmaceutical firm, Viking Therapeutics, Inc. (NASDAQ:VKTX), based in San Diego, develops novel ...